Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI in Pompe Disease Patients Previously Treated With Myozyme
NCT00701701Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Dec 2008
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, open-label trial of cyclophosphamide, rituximab and methotrexate in Pompe disease (2 arms), sponsored by Sanofi. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 18 months. Started Dec 2008; status: terminated.
02
Drugs
cyclophosphamiderituximabmethotrexate
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00701701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701701.